Literature DB >> 20045793

Dramatic complete response in patient with lung adenocarcinoma.

Sara Serrano Solares1, Dolores Isla Casado, María Jesús Vidal Losada, María Tobeña Puyal, Ana Isabel Ferrer Pérez, Isabel Pajares.   

Abstract

The poor prognosis of non-small-cell lung cancer (NSCLC) is changing thanks to the constant development of new treatments and the introduction of target therapies, even in stage IV disease. This patient had bone metastases when he was diagnosed. Maintenance treatment, a much discussed topic nowadays, achieved a dramatic complete response.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20045793     DOI： 10.1007/s12094-009-0455-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  6 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

2.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

3.  Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

Authors:  Panos M Fidias; Shaker R Dakhil; Alan P Lyss; David M Loesch; David M Waterhouse; Jane L Bromund; Ruqin Chen; Maria Hristova-Kazmierski; Joseph Treat; Coleman K Obasaju; Martin Marciniak; John Gill; Joan H Schiller
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

Review 4.  Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.

Authors: 
Journal:  J Clin Oncol       Date:  2008-08-04       Impact factor: 44.544

5.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

6.  Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).

Authors:  Koji Takeda; Toyoaki Hida; Tosiya Sato; Masahiko Ando; Takashi Seto; Miyako Satouchi; Yukito Ichinose; Nobuyuki Katakami; Nobuyuki Yamamoto; Shinzoh Kudoh; Jiichiro Sasaki; Kaoru Matsui; Koichi Takayama; Tatsuhiko Kashii; Yasuo Iwamoto; Toshiyuki Sawa; Isamu Okamoto; Takayasu Kurata; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.